KMDA vs. NKTX, NKTR, SBTX, ERAS, ADCT, ATAI, MRSN, VSTM, AVIR, and PGEN
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Nkarta (NKTX), Nektar Therapeutics (NKTR), Silverback Therapeutics (SBTX), Erasca (ERAS), ADC Therapeutics (ADCT), Atai Life Sciences (ATAI), Mersana Therapeutics (MRSN), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Kamada (NASDAQ:KMDA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
Kamada currently has a consensus target price of $11.00, suggesting a potential upside of 104.84%. Nkarta has a consensus target price of $17.83, suggesting a potential upside of 163.03%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Kamada.
Kamada has a net margin of 8.33% compared to Nkarta's net margin of 0.00%. Kamada's return on equity of 5.50% beat Nkarta's return on equity.
Kamada has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
In the previous week, Nkarta had 4 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Nkarta and 3 mentions for Kamada. Kamada's average media sentiment score of 0.81 beat Nkarta's score of 0.11 indicating that Kamada is being referred to more favorably in the media.
Kamada received 261 more outperform votes than Nkarta when rated by MarketBeat users. However, 72.73% of users gave Nkarta an outperform vote while only 65.05% of users gave Kamada an outperform vote.
20.4% of Kamada shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 5.6% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Kamada has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Summary
Kamada beats Nkarta on 11 of the 16 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
